IDEXX Laboratories, Inc. $IDXX is Blair William & Co. IL’s 8th Largest Position

Blair William & Co. IL lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,001,375 shares of the company’s stock after selling 30,411 shares during the quarter. IDEXX Laboratories makes up approximately 1.8% of Blair William & Co. IL’s portfolio, making the stock its 8th biggest position. Blair William & Co. IL owned 1.25% of IDEXX Laboratories worth $677,460,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in IDXX. Empowered Funds LLC raised its holdings in shares of IDEXX Laboratories by 6.6% during the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after acquiring an additional 95 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $265,000. Jump Financial LLC raised its holdings in shares of IDEXX Laboratories by 1,006.4% during the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after acquiring an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at approximately $164,000. Finally, Sei Investments Co. raised its holdings in shares of IDEXX Laboratories by 218.7% during the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after acquiring an additional 82,755 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $573.00 on Wednesday. The stock has a fifty day simple moving average of $563.14 and a two-hundred day simple moving average of $624.14. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The company has a market cap of $45.20 billion, a price-to-earnings ratio of 42.19, a price-to-earnings-growth ratio of 3.12 and a beta of 1.55. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.41 by $0.06. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on IDXX shares. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup started coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Stifel Nicolaus decreased their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.